Search research articles
Contact Us
Filters
Showing results (1-10 of 37) with videos related to
Page
of 4
Sort By:
Antimicrobial Agents and Chemotherapy
|
March 30, 2004
Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine
Chris Stone, Mounir Ait-Khaled, Charles Craig, et al.
Antimicrobial Agents and Chemotherapy
|
April 8, 2024
Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1
Hardik Chandasana, Rajendra Singh, Kimberly Adkison, et al.
Journal of Clinical Pharmacology
|
July 16, 2024
Population Pharmacokinetic Analysis of Dolutegravir in Treatment-Experienced Adults Living with HIV-1
Hardik Chandasana, Mark Bush, Mounir Ait-Khaled, et al.
AIDS (London, England)
|
August 13, 2002
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine
Mounir Ait-Khaled, Chris Stone, Gillian Amphlett, et al.
Antiviral Therapy
|
February 22, 2007
Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen
Diane Descamps, Mounir Ait-Khaled, Charles Craig, et al.
Open Forum Infectious Diseases
|
May 13, 2024
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study
Mounir Ait-Khaled, James Oyee, Adrian Yit Reen Ooi, et al.
Clinical Pharmacology and Therapeutics
|
July 17, 2024
Integrated Population Exposure-Response of Dolutegravir in HIV-1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient Characteristics
Hardik Chandasana, Mark Bush, Cindy Vavro, et al.
Antiviral Therapy
|
May 14, 2003
HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study
Mounir Ait-Khaled, Abdelrahim Rakik, Philip Griffin, et al.
Antimicrobial Agents and Chemotherapy
|
October 15, 2008
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials
Anne-Geneviève Marcelin, Philippe Flandre, Jean-Michel Molina, et al.
The Journal of Infectious Diseases
|
August 27, 2002
Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial
Deenan Pillay, A Sarah Walker, Diana M Gibb, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 37) with videos related to
Sort By:
Page
of 4
Antimicrobial Agents and Chemotherapy
|
March 30, 2004
Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine
Chris Stone, Mounir Ait-Khaled, Charles Craig, et al.
Antimicrobial Agents and Chemotherapy
|
April 8, 2024
Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1
Hardik Chandasana, Rajendra Singh, Kimberly Adkison, et al.
Journal of Clinical Pharmacology
|
July 16, 2024
Population Pharmacokinetic Analysis of Dolutegravir in Treatment-Experienced Adults Living with HIV-1
Hardik Chandasana, Mark Bush, Mounir Ait-Khaled, et al.
AIDS (London, England)
|
August 13, 2002
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine
Mounir Ait-Khaled, Chris Stone, Gillian Amphlett, et al.
Antiviral Therapy
|
February 22, 2007
Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen
Diane Descamps, Mounir Ait-Khaled, Charles Craig, et al.
Open Forum Infectious Diseases
|
May 13, 2024
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study
Mounir Ait-Khaled, James Oyee, Adrian Yit Reen Ooi, et al.
Clinical Pharmacology and Therapeutics
|
July 17, 2024
Integrated Population Exposure-Response of Dolutegravir in HIV-1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient Characteristics
Hardik Chandasana, Mark Bush, Cindy Vavro, et al.
Antiviral Therapy
|
May 14, 2003
HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study
Mounir Ait-Khaled, Abdelrahim Rakik, Philip Griffin, et al.
Antimicrobial Agents and Chemotherapy
|
October 15, 2008
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials
Anne-Geneviève Marcelin, Philippe Flandre, Jean-Michel Molina, et al.
The Journal of Infectious Diseases
|
August 27, 2002
Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial
Deenan Pillay, A Sarah Walker, Diana M Gibb, et al.
Page
of 4